Neuroprotection and brain cholesterol biosynthesis in Huntington's disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 37, 2010, Pages

  Valenza, Marta ^a   Cattaneo, Elena ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLESTEROL; HUNTINGTIN; HYDROLASE INHIBITOR; MESSENGER RNA; SIRTUIN 2; SIRTUIN 2 INHIBITOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRINUCLEOTIDE; UNCLASSIFIED DRUG; SIRT2 PROTEIN, HUMAN;

AMINO TERMINAL SEQUENCE; BRAIN; CELL DEATH; CHOLESTEROL SYNTHESIS; COMPETITIVE INHIBITION; CORPUS STRIATUM; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUNTINGTON CHOREA; LETTER; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; HOMEOSTASIS; HUMAN; HUNTINGTON DISEASE; METABOLISM;

BRAIN; CHOLESTEROL; HOMEOSTASIS; HUMANS; HUNTINGTON DISEASE; SIRTUIN 2;

EID: 77957991623     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1006783107     Document Type: Letter

References (5)

1. Luthi-Carter R, et al. (2010) SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci USA 107:7927-7932.
2. Zala D, et al. (2005) Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment. Neurobiol Dis 20:785-798. (Pubitemid 41622214)
3. Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 90:905-981.
4. Katsuno M, Adachi H, Sobue G (2009) Getting a handle on Huntington's disease: The case for cholesterol. Nat Med 15:253-254.
5. Valenza M, et al. (2010) Cholesterol defect is marked across multiple rodent models of Huntington's disease and is manifest in astrocytes. J Neurosci 30:10844-10850.